<DOC>
	<DOCNO>NCT01378598</DOCNO>
	<brief_summary>Research find patient sometimes trouble obtain oral ( mouth ) cancer medication , understand take pill , handle side effect relate drug , remember take medication . The purpose research study direct care nurse ( DCNs ) Thoracic Oncology Program ( TOP ) clinic provide teach follow-up patient start erlotinib ( use teach tool ) test feasibility provide education follow-up . This study also evaluate increase knowledge erlotinib help participant manage side effect stay erlotinib without interruption .</brief_summary>
	<brief_title>Enhancing Adherence Knowledge Erlotinib Patients Wtih Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>- Participants non-small cell lung cancer ask join study decide health care provider start treatment erlotinib ( pill ) . - Educational Session 1 ( Day erlotinib prescribe ) : During clinic visit physician nurse practitioner provide participant DFCI Erlotinib Fact Sheet review take oral cancer medication possible side effect watch . The TOP nurse discus study consent participant . The TOP nurse also provide participant Erlotinib Drug Log instruct use keep track take erlotinib . - Educational Session 2 ( Within 72 hour start erlotinib ) : During educational session , participant talk TOP nurse phone clinic . The TOP nurse use oral cancer medication teach tool ( MOATT - Parts 1-4 ) provide additional education erlotinib . The MOATT tool develop Multinational Association Supportive Care Cancer . This session take 20-30 minute . Feasibility information also record nurse . - Educational Session 3 ( Phone follow-up 72 hour Session 2 ) : During phone session , TOP nurse administer Parts 3-4 MOATT discuss side effect participant experience . This session take 15-30 minute . Feasibility information also document . - Educational Session 4 ( First clinic visit start Erlotinib ) : The TOP nurse meet participant first DFCI clinic visit ( physician nurse practitioner ) , start erlotinib . During session participant complete Morisky Medication Adherence Scale 8-Item ( MMAS-8 ) , Knowledge Rating Scale , demographic form . Parts 3-4 MOATT also administer , Erlotinib Drug Log collect , side effect discussed/recorded . This meeting add 30-40 minute clinic visit . - After participant complete Educational Session 4 , participation study end .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>18 year age old Nonsmall cell lung cancer diagnosis Patient/provider decision start erlotinib monotherapy No prior treatment erlotinib Willingness follow protocol visit schedule Ability understand converse English No major physical psychological limitation would interfere study participation Not participate study involve nurse/patient interaction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>erlotinib</keyword>
	<keyword>educational intervention</keyword>
	<keyword>direct care nurse</keyword>
</DOC>